Mcmaster University

Allelix Biopharmaceuticals Inc.

Bristol Meyers Squibb Company

Jack Gauldie

Mohammed Shoyab

Peter Michael Lansdorp

Thomas J Brown

Richards, Carl

Carl D Richards

A method for decreasing metalloproteinase activity in a patient that comprises the step of administering to said patient a therapeutic composition comprising the cytokine oncostatin-M, or a biologically active fragment, mutant, analog or fusion construct thereof. Also, a method for increasing TIMP activity in a patient that comprises the step of administering to said patient a therapeutic composition comprising the cytokine oncostatin-M, or a biologically active fragment, mutant, analog or fusion construct thereof. In addition a method for inhibiting or treating progression of a tumor in a patient that comprises the step of administering to said patient a therapeutic composition comprising oncostatin-M, or a biologically active fragment, mutant, analog, or fusion construct thereof, said method being effective to inhibit invasion by a tumor cell through an extracellular space, extracellular matrix, basement membrane, interstitial tissue or connective tissue. Also methods effective to treat inflammatory or degenerative disease, methods effective to stimulate erythropoiesis, and methods effective to regulate tissue remodeling and to promote healing of injury.

Regulation of cellular invasiveness

Interferon .beta..sub.2 has been identified as the major factor responsible for stimulating hepatocytes to produce anti-inflammatory agents. A method for its use in so stimulating hepatocytes is described herein.

Treating inflammation with hepatocyte stimulating factor interferon

Growing community of inventors

Hamilton, Canada

Jack Gauldie